Genovis AB

Historical price data

Genovis AB is a publicly traded Swedish biotech tools company with a mission to accelerate biologic drug development through its proprietary SmartEnzymes™ platform. The company has achieved a leading position as a supplier of high-specificity enzymes for antibody analysis and processing, serving top pharmaceutical and biotech firms globally. Its strategy focuses on expanding its enzyme toolkit into new applications such as gene therapy and large-scale bioprocessing, while leveraging a capital-efficient, high-margin business model. With a market valuation exceeding $1.1 billion, Genovis has demonstrated significant growth and market validation.

The SmartEnzymes™ platform consists of proprietary, engineered recombinant enzymes designed for highly specific cleavage and modification of proteins, particularly antibodies, enabling precise analysis, fragmentation, and processing of complex biologics.

Genovis competes with broad-based reagent suppliers like Thermo Fisher and New England Biolabs, but maintains an advantage through superior enzyme specificity and deep application expertise in antibody engineering. Its primary competition often comes from in-house, non-standardized methods used by large biopharma firms.